Literature DB >> 17621515

Estimating premorbid general cognitive functioning for children and adolescents using the American Wechsler Intelligence Scale for Children-Fourth Edition: demographic and current performance approaches.

Mike R Schoenberg1, Rael T Lange, Tracey A Brickell, Donald H Saklofske.   

Abstract

Neuropsychologic evaluation requires current test performance be contrasted against a comparison standard to determine if change has occurred. An estimate of premorbid intelligence quotient (IQ) is often used as a comparison standard. The Wechsler Intelligence Scale for Children-Fourth Edition (WISC-IV) is a commonly used intelligence test. However, there is no method to estimate premorbid IQ for the WISC-IV, limiting the test's utility for neuropsychologic assessment. This study develops algorithms to estimate premorbid Full Scale IQ scores. Participants were the American WISC-IV standardization sample (N = 2172). The sample was randomly divided into 2 groups (development and validation). The development group was used to generate 12 algorithms. These algorithms were accurate predictors of WISC-IV Full Scale IQ scores in healthy children and adolescents. These algorithms hold promise as a method to predict premorbid IQ for patients with known or suspected neurologic dysfunction; however, clinical validation is required.

Entities:  

Mesh:

Year:  2007        PMID: 17621515     DOI: 10.1177/0883073807301925

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  2 in total

1.  Predicting premorbid memory functioning in older adults.

Authors:  Kevin Duff
Journal:  Appl Neuropsychol       Date:  2010-10

2.  Utility of the General Ability Index (GAI) and Cognitive Proficiency Index (CPI) with survivors of pediatric brain tumors: Comparison to Full Scale IQ and premorbid IQ estimates.

Authors:  Lisa S Kahalley; Amanda Winter-Greenberg; Heather Stancel; M Douglas Ris; Marsha Gragert
Journal:  J Clin Exp Neuropsychol       Date:  2016-06-13       Impact factor: 2.475

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.